Papillary Thyroid Cancer Clinical Trial
Official title:
The Role of Oxidative Stress and Mitochondrial TERT in the Progression and Therapeutic Resistance of Papillary Thyroid Cancer.
Oxidative stress (OS) could be involved in the progression of papillary thyroid cancer (PTC). Indeed, thyroid differentiation genes are silenced by a mechanism controlled by NOX4-derived OS. On the other hand, TERT contributes to mitochondrial OS protection, which could increase the resistance of cancer cells to therapeutic agents. The investigators aim to address the role of OS and mitochondrial TERT in the progression and therapeutic resistance of PTC. OS and TERT subcellular localization will be investigated in 150 PTCs and correlated to the genetic and expression profile of the tumors and to the clinical and prognostic features of the patients. Mechanisms implicated in TERT mitochondrial migration and the contribution of mitochondrial TERT to tumor progression will be investigated in cancer cell lines and primary cell cultures. This study will allow to identify OS as a marker of therapeutic resistance in PTC and will open new opportunities for the development of novel treatments targeting ROS generation/TERT nuclear export.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT01441154 -
Metabolic Effects of Synthetic Thyroid Hormone for Thyroid Cancer Treatment
|
||
| Active, not recruiting |
NCT04544111 -
PDR001 Combination Therapy for Radioiodine-Refractory Thyroid Cancer
|
Phase 2 | |
| Recruiting |
NCT03469011 -
A Study to Try to Bring Back Radioiodine Sensitivity in Patients With Advanced Thyroid Cancer.
|
Phase 1 | |
| Recruiting |
NCT04076514 -
The Role of Central Neck Dissection in Stage N0 Papillary Thyroid Carcinoma
|
||
| Completed |
NCT06439745 -
More Than 50% of the Patients With Clinically Unifocal T1b/Small T2 Node Negative Papillary Thyroid Carcinoma Scheduled for Thyroid Lobectomy May Require Completion Thyroidectomy if the Nodal Status is Evaluated
|
||
| Active, not recruiting |
NCT01723202 -
Dabrafenib With or Without Trametinib in Treating Patients With Recurrent Thyroid Cancer
|
Phase 2 | |
| Recruiting |
NCT05500508 -
Oral AMXT 1501 Dicaprate in Combination With IV DFMO
|
Phase 1/Phase 2 | |
| Active, not recruiting |
NCT02568267 -
Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions)
|
Phase 2 | |
| Unknown status |
NCT02140476 -
Comparative Analysis Between Bipolar Device and Conventional Tie & Suture Technique in Thyroidectomy
|
N/A | |
| Recruiting |
NCT06286631 -
Prediction of Lymph Node Metastasis in Patients With Thyroid Malignancy by a New Scale
|
||
| Completed |
NCT06325787 -
Image-guided Thermal Ablation vs. Lobectomy for Solitary Papillary Thyroid Microcarcinoma
|
N/A | |
| Terminated |
NCT01974284 -
Percutaneous Ethanol Injection for Primary Papillary Thyroid Microcarcinoma
|
N/A | |
| Active, not recruiting |
NCT00984191 -
Pilot 99mTechnetium-MIBI Single Photon Emission Computed Tomography - Computed Tomography (SPECT-CT) in Papillary Carcinoma (CA) Thyroid
|
N/A | |
| Active, not recruiting |
NCT04731467 -
A Study of CM24 in Combination With Nivolumab in Adults With Advanced Solid Tumors
|
Phase 1/Phase 2 | |
| Recruiting |
NCT05668962 -
Restor. I-131 Upt. + Selpercatinib in RET F-P RAI-R TC
|
Phase 2 | |
| Completed |
NCT02178345 -
Predictive MRI Metrics for Tumor Aggressiveness in Papillary Thyroid Cancer
|
||
| Not yet recruiting |
NCT06133374 -
Concordance of Molecular Classification Based on Fine Needle Biopsy (FNB) and Surgical Samples
|
||
| Completed |
NCT03470259 -
Precision Thyroid Cancer Surgery With Molecular Fluorescent Guided Imaging
|
Phase 1 | |
| Active, not recruiting |
NCT04129411 -
Treatment of Papillary Thyroid Carcinoma With Radiofrequency Ablation
|
N/A | |
| Recruiting |
NCT03899792 -
A Study of Oral LOXO-292 (Selpercatinib) in Pediatric Participants With Advanced Solid or Primary Central Nervous System (CNS) Tumors
|
Phase 1/Phase 2 |